ArticleChinese medical journal2026
Ultrasound‑responsive nano‑contrast agents co‑delivering CIITA ‑siRNA and rapamycin for targeted therapy against Hashimoto thyroiditis.
Article in Chinese medical journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHashimoto thyroiditis (HT) is a common autoimmune thyroid disease for which effective treatments capable of suppressing local autoimmune injury remain limited. This study aimed to develop an ultrasound-responsive anti-inflammatory nano-contrast agent (AINA) for the targeted delivery of MHC class II transactivator (CIITA)-small interfering ribonucleic acid ( CIITA -siRNA) and rapamycin to thyroid tissue.
methodsThyroid tissue samples were obtained from patients undergoing total thyroidectomy at Qilu Hospital of Shandong University from March to April 2024. After pathological evaluation, samples from three patients with HT and three patients without HT were included. CIITA and human leukocyte antigen DR isotype ( HLA-DR ) expression was assessed using transcriptomic sequencing and quantitative reverse transcription polymerase chain reaction. AINAs were constructed with an erythrocyte-membrane shell carrying rapamycin and a core containing CIITA -siRNA-loaded, trans-activator of transcription (TAT)-modified mesoporous silica nanoparticles and liquid perfluorohexane. Their physicochemical properties, ultrasound imaging performance, cellular uptake, therapeutic effects, and preliminary safety were evaluated in Nthy-ori 3-1 cells, Jurkat cells, and NOD.H-2h 4 mice.
resultsAINAs had a mean diameter of 255 nm and a polydispersity index of 0.23. More than 90% of CIITA -siRNA was loaded onto the mesoporous silica nanoparticles, and the optimized preparation achieved a rapamycin encapsulation efficiency of approximately 75%. In vitro , ultrasound-assisted AINAs reduced Interleukin-23-induced reactive oxygen species accumulation and apoptosis in thyroid cells and suppressed CIITA and HLA-DR expression, antigen presentation, and Jurkat T-cell activation. In vivo , ultrasound enhanced the accumulation of AINAs in thyroid tissue. Treatment with AINAs plus ultrasound alleviated thyroid inflammation, reduced local CD3 + and CD4 + T-cell infiltration and serum thyroid autoantibody levels, and caused no apparent pathological injury to major organs.
conclusionsUltrasound-responsive AINAs enabled the targeted delivery of CIITA -siRNA and rapamycin to thyroid tissue and showed anti-inflammatory and thyroid-protective effects in cellular and animal models of HT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.